E-resources
-
Batlevi, Connie L.; Sha, Fushen; Alperovich, Anna; Ni, Ai; Smith, Katy; Ying, Zhitao; Gerecitano, John F.; Hamlin, Paul A.; Horwitz, Steve M.; Joffe, Erel; Kumar, Anita; Matasar, Matthew J.; Moskowitz, Alison J.; Moskowitz, Craig H.; Noy, Ariela; Owens, Colette; Palomba, Lia M.; Straus, David; von Keudell, Gottfried; Zelenetz, Andrew D.; Seshan, Venkatraman E.; Luminari, Stefano; Marcheselli, Luigi; Federico, Massimo; Younes, Anas
European journal of cancer, February 2020, 2020-02-00, 20200201, Volume: 126Journal Article
Previous studies reported that early progression of disease (POD) after initial therapy predicted poor overall survival (OS) in patients with follicular lymphoma (FL). Here, we investigated whether pre-treatment imaging modality had an impact on prognostic significance of POD. In this retrospective study, we identified 1088 patients with grade I–IIIA FL; of whom, 238 patients with stage II–IV disease were initially treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), and 346 patients were treated with rituximab-based chemotherapy. Patients (N = 484) from the FOLL05 study served as an independent validation cohort. We risk-stratified patients based on pre-treatment radiographic imaging (positron-emission tomography PET versus computed tomography CT) and early POD status using event-defining and landmark analyses. A competing risk analysis evaluated the association between early POD and histologic transformation. In the discovery cohort, patients with POD within 24 months (PFS24) of initiating R-CHOP therapy had a 5-year OS of 57.6% for CT-staged patients compared with 70.6% for PET-staged patients. In the validation cohort, the 5-year OS for patients with early POD was 53.9% and 100% in CT- and PET-staged patients, respectively. The risk of histologic transformation in patients whose disease progressed within one year of initiating therapy was higher in CT-staged patients than in PET-staged patients (16.7% versus 6.3%, respectively), which was associated with a 9.7-fold higher risk of death. In FL, pre-treatment PET staging reduced the prognostic impact of early POD compared with CT staging. Patients with early POD and no histologic transformation have an extended OS with standard therapy. •Early progression after first-line treatment in follicular lymphoma is a marker of poor prognosis.•Positron-emission tomography (PET) staging possibly identifies patients with highest risk of poor outcomes.•PET staging reduces the prognostic impact of early progression likely by excluding patients with early transformation.•Patients with early progression and early transformation have the highest risk of poor outcomes.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.